Dormant tumor cells as a therapeutic target?

Cancer Letters

Volumn 267, Issue 1, 2008, Pages 10-17

  Quesnel, Bruno ^a,b  

^a Institut de Recherche sur le Cancer de Lille   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

B7 H1; Cytotoxic T cells; Imatinib; NK; PD L1; Stem cell; Tumor dormancy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; B7 ANTIGEN; CYTARABINE; DASATINIB; IMATINIB; JANUS KINASE; MELPHALAN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ANGIOGENESIS; AUTOCRINE EFFECT; CANCER CELL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DORMANCY; DRUG MECHANISM; ENZYME REGULATION; EPIGENETICS; GAMMA IRRADIATION; GENE SILENCING; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MELANOMA; MICROENVIRONMENT; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SHORT SURVEY; TARGET CELL; TUMOR CELL; TUMOR IMMUNITY;

EID: 45949108135     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.055     Document Type: Review

References (61)

1. Davis T.A., Maloney D.G., Czerwinski D.K., Liles T.M., and Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92 (1998) 1184-1190
2. Meng S., Tripathy D., Frenkel E.P., Shete S., Naftalis E.Z., Huth J.F., Beitsch P.D., Leitch M., Hoover S., Euhus D., Haley B., Morrison L., Fleming T.P., Herlyn D., Terstappen L.W., Fehm T., Tucker T.F., Lane N., Wang J., and Uhr J.W. Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research 10 (2004) 8152-8162
3. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G., Uhr J.W., and Terstappen L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research 10 (2004) 6897-6904
4. Pfitzenmaier J., Ellis W.J., Hawley S., Arfman E.W., Klein J.R., Lange P.H., and Vessella R.L. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urologic Oncology 25 (2007) 214-220
5. Vessella R.L., Pantel K., and Mohla S. Tumor cell dormancy: an NCI workshop report. Cancer Biological Therapy 6 (2007)
6. Schardt J.A., Meyer M., Hartmann C.H., Schubert F., Schmidt-Kittler O., Fuhrmann C., Polzer B., Petronio M., Eils R., and Klein C.A. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8 (2005) 227-239
7. Almog N., Henke V., Flores L., Hlatky L., Kung A.L., Wright R.D., Berger R., Hutchinson L., Naumov G.N., Bender E., Akslen L.A., Achilles E.G., and Folkman J. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB Journal 20 (2006) 947-949
8. Indraccolo S., Stievano L., Minuzzo S., Tosello V., Esposito G., Piovan E., Zamarchi R., Chieco-Bianchi L., and Amadori A. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 4216-4221
9. Naumov G.N., Bender E., Zurakowski D., Kang S.Y., Sampson D., Flynn E., Watnick R.S., Straume O., Akslen L.A., Folkman J., and Almog N. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. Journal of the National Cancer Institute 98 (2006) 316-325
10. Verheul H.M., Voest E.E., and Schlingemann R.O. Are tumours angiogenesis-dependent?. The Journal of Pathology 202 (2004) 5-13
11. Aguirre Ghiso J.A., Kovalski K., and Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. The Journal of Cell Biology 147 (1999) 89-104
12. Weaver V.M., Lelievre S., Lakins J.N., Chrenek M.A., Jones J.C., Giancotti F., Werb Z., and Bissell M.J. Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2 (2002) 205-216
13. Aguirre-Ghiso J.A. Models mechanisms and clinical evidence for cancer dormancy. Nature Reviews 7 (2007) 834-846
14. Naumov G.N., Akslen L.A., and Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (Georgetown, Tex) 5 (2006) 1779-1787
15. Hedley B.D., Allan A.L., and Chambers A.F. Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. Future Oncology (London, England) 2 (2006) 627-641
16. Marches R., Scheuermann R., and Uhr J. Cancer dormancy: from mice to man. Cell Cycle (Georgetown, Tex) 5 (2006) 1772-1778
17. Page K., and Uhr J.W. Mathematical models of cancer dormancy. Leukemia & Lymphoma 46 (2005) 313-327
18. Uhr J.W., and Marches R. Dormancy in a model of murine B cell lymphoma. Seminars in Cancer Biology 11 (2001) 277-283
19. Marches R., Hsueh R., and Uhr J.W. Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 8711-8715
20. Farrar J.D., Katz K.H., Windsor J., Thrush G., Scheuermann R.H., Uhr J.W., and Street N.E. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. Journal of Immunology 162 (1999) 2842-2849
21. Marches R., Scheuermann R.H., and Uhr J.W. Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM. Cancer Research 58 (1998) 691-697
22. Vitetta E.S., Tucker T.F., Racila E., Huang Y.W., Marches R., Lane N., Scheuermann R.H., Street N.E., Watanabe T., and Uhr J.W. Tumor dormancy cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood 89 (1997) 4425-4436
23. Racila E., Hsueh R., Marches R., Tucker T.F., Krammer P.H., Scheuermann R.H., and Uhr J.W. Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 2165-2168
24. Yefenof E., Picker L.J., Scheuermann R.H., Tucker T.F., Vitetta E.S., and Uhr J.W. Cancer dormancy: isolation and characterization of dormant lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 1829-1833
25. Saudemont A., and Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 104 (2004) 2124-2133
26. Saudemont A., Buffenoir G., Denys A., Desreumaux P., Jouy N., Hetuin D., Bauters F., Fenaux P., and Quesnel B. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia 16 (2002) 1637-1644
27. Vereecque R., Buffenoir G., Preudhomme C., Hetuin D., Bauters F., Fenaux P., and Quesnel B. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Therapy 7 (2000) 1312-1316
28. Roberts W.M., Estrov Z., Ouspenskaia M.V., Johnston D.A., McClain K.L., and Zipf T.F. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. The New England Journal of Medicine 336 (1997) 317-323
29. Zhou G., Lu Z., McCadden J.D., Levitsky H.I., and Marson A.L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. The Journal of Experimental Medicine 200 (2004) 1581-1592
30. Khazaie K., Prifti S., Beckhove P., Griesbach A., Russell S., Collins M., and Schirrmacher V. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 7430-7434
31. Mahnke Y.D., Schwendemann J., Beckhove P., and Schirrmacher V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 115 (2005) 325-336
32. Muller M., Gounari F., Prifti S., Hacker H.J., Schirrmacher V., and Khazaie K. EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells. Cancer Research 58 (1998) 5439-5446
33. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumour dormant state. Seminars in Cancer Biology 11 (2001) 285-295
34. Yamshchikov G.V., Mullins D.W., Chang C.C., Ogino T., Thompson L., Presley J., Galavotti H., Aquila W., Deacon D., Ross W., Patterson J.W., Engelhard V.H., Ferrone S., and Slingluff Jr. C.L. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. Journal of Immunology 174 (2005) 6863-6871
35. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., and Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907
36. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annual Review of Immunology 23 (2005) 515-548
37. Lohr J., Knoechel B., Jiang S., Sharpe A.H., and Abbas A.K. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nature Immunology 4 (2003) 664-669
38. Tirapu I., Huarte E., Guiducci C., Arina A., Zaratiegui M., Murillo O., Gonzalez A., Berasain C., Berraondo P., Fortes P., Prieto J., Colombo M.P., Chen L., and Melero I. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Research 66 (2006) 2442-2450
39. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., and Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27 (2007) 111-122
40. Saudemont A., Hamrouni A., Marchetti P., Liu J., Jouy N., Hetuin D., Colucci F., and Quesnel B. Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Research 67 (2007) 4491-4498
41. Liu J., Joha S., Idziorek T., Corm S., Hetuin D., Philippe N., Preudhomme C., and Quesnel B. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia (2008) Jan 24 [Epub ahead of print]
42. Saudemont A., Jouy N., Hetuin D., and Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 105 (2005) 2428-2435
43. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., and Caligiuri M.A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100 (2002) 1935-1947
44. Liu J., Hamrouni A., Wolowiec D., Coiteux V., Kuliczkowski K., Hetuin D., Saudemont A., and Quesnel B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110 (2007) 296-304
45. Lee S.J., Jang B.C., Lee S.W., Yang Y.I., Suh S.I., Park Y.M., Oh S., Shin J.G., Yao S., Chen L., and Choi I.H. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Letters 580 (2006) 755-762
46. Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., Barry J.J., Cachola K.E., Murray J.C., Tihan T., Jensen M.C., Mischel P.S., Stokoe D., and Pieper R.O. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine 13 (2007) 84-88
47. Quesnel B. MEK inhibitor: the MM magic bullet?. Blood 110 (2007) 1402a-1403a
48. Tai Y.T., Fulciniti M., Hideshima T., Song W., Leiba M., Li X.F., Rumizen M., Burger P., Morrison A., Podar K., Chauhan D., Tassone P., Richardson P., Munshi N.C., Ghobrial I.M., and Anderson K.C. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 110 (2007) 1656-1663
49. Jovasevic V.M., Gorelik L., Bluestone J.A., and Mokyr M.B. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. Journal of Immunology 172 (2004) 1449-1454
50. Jovasevic V.M., and Mokyr M.B. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. Journal of Immunology 167 (2001) 4895-4901
51. Ben-Efraim S. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Current Drug Targets 2 (2001) 197-212
52. Sojka D.K., Donepudi M., Bluestone J.A., and Mokyr M.B. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. Journal of Immunology 164 (2000) 6230-6236
53. Vereecque R., Buffenoir G., Gonzalez R., Cambier N., Hetuin D., Bauters F., Fenaux P., and Quesnel B. Gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells. British Journal of Haematology 108 (2000) 825-831
54. Vereecque R., Saudemont A., Depil S., Corm S., Andrieux J., Soenen-Cornu V., and Quesnel B. Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells. Cancer Immunology Immunotherapy 53 (2004) 793-798
55. Vereecque R., Saudemont A., and Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 18 (2004) 1223-1230
56. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., Metivier D., Larochette N., van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., and Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine 13 (2007) 54-61
57. Obeid M., Panaretakis T., Tesniere A., Joza N., Tufi R., Apetoh L., Ghiringhelli F., Zitvogel L., and Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Research 67 (2007) 7941-7944
58. Shachaf C.M., and Felsher D.W. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Research 65 (2005) 4471-4474
59. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., and Felsher D.W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 (2004) 1112-1117
60. Huettner C.S., Zhang P., Van Etten R.A., and Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genetics 24 (2000) 57-60
61. von dem Borne P.A., van Luxemburg-Heijs S.A., Heemskerk M.H., Jedema I., Mulder A., Willemze R., and Falkenburg J.H. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia 20 (2006) 1040-1046